OTCPK:GIKLY (Spain) Also Trade In: Austria Germany Mexico Spain UK USA

Grifols SA $ 14.90 0 (0%)

Volume:

150

Avg Vol (1m):

725

Market Cap $:

20.40 Bil

Enterprise Value $:

29.78 Bil

P/E (TTM):

24.13

P/B:

3.09

5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

View Full Chart

What is PE Ratio (TTM)?

Current and historical daily P/E ratio for Grifols SA () from 2008 to Jan 17 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Grifols stock (GIKLY) PE ratio as of Jan 17 2021 is 24.13. More Details

Grifols PE Ratio (TTM) Chart

EMBED

Grifols PE Ratio (TTM) Historical Data

View and export this data going back to 2008. Start your Free Trial

Total 1244

Grifols PE Ratio (TTM) Historical Data
Date	PE Ratio (TTM) Data	Date	PE Ratio (TTM) Data
2021-01-17	26.2	2020-11-11	25.2
2021-01-15	26.2	2020-11-10	25.2
2021-01-14	26.2	2020-11-09	25.2
2021-01-13	25.8	2020-11-06	25.2
2021-01-12	25.8	2020-11-05	25.2
2021-01-11	25.8	2020-11-04	25.2
2021-01-08	25.8	2020-11-03	25.2
2021-01-07	27.2	2020-11-02	25.2
2021-01-06	27.2	2020-10-30	25.2
2021-01-05	27.2	2020-10-29	25.2
2021-01-04	27.2	2020-10-28	25.2
2020-12-31	27.2	2020-10-27	27.3
2020-12-30	27.2	2020-10-26	27.3
2020-12-29	27.2	2020-10-23	27.3
2020-12-28	27.2	2020-10-22	27.3
2020-12-24	27.2	2020-10-21	27.3
2020-12-23	27.2	2020-10-20	27.3
2020-12-22	27.2	2020-10-19	27.3
2020-12-21	27.2	2020-10-16	27.5
2020-12-18	27.2	2020-10-15	27.5
2020-12-17	26.0	2020-10-14	24.7
2020-12-16	26.0	2020-10-13	24.7
2020-12-15	26.0	2020-10-12	24.7
2020-12-14	26.0	2020-10-09	24.7
2020-12-11	26.0	2020-10-08	24.7
2020-12-10	25.3	2020-10-07	24.7
2020-12-09	25.3	2020-10-06	24.7
2020-12-08	25.3	2020-10-05	24.7
2020-12-07	25.3	2020-10-02	24.7
2020-12-04	25.5	2020-10-01	24.7
2020-12-03	25.5	2020-09-30	24.7
2020-12-02	25.5	2020-09-29	24.7
2020-12-01	25.5	2020-09-28	24.7
2020-11-30	25.5	2020-09-25	31.3
2020-11-27	25.5	2020-09-24	31.3
2020-11-25	25.5	2020-09-23	31.3
2020-11-24	27.2	2020-09-22	31.3
2020-11-23	27.2	2020-09-21	31.3
2020-11-20	27.2	2020-09-18	31.3
2020-11-19	27.2	2020-09-17	31.3
2020-11-18	27.2	2020-09-16	31.3
2020-11-17	27.2	2020-09-15	31.3
2020-11-16	27.2	2020-09-14	31.3
2020-11-13	27.2	2020-09-11	31.3
2020-11-12	25.2	2020-09-10	31.3

Grifols PE Ratio (TTM) Comparison

Company	Market Cap(Mil)	PE Ratio (TTM)

Business Description

Industry Healthcare » Drug Manufacturers » NAICS : 325412

Compare NYSE:JNJ XSWX:ROG NYSE:PFE XSWX:NOVN NYSE:MRK NYSE:ABBV NYSE:LLY LSE:AZN NYSE:BMY NAS:AMGN XPAR:SAN LSE:GSK NAS:GILD TSE:4519 FRA:A60 NYSE:AGN XTER:BAYN SHSE:600276 TSE:4568 NAS:BIIB

Traded in other countries GRF.Austria G0FB.Germany GRFP.Mexico GRF.Spain 0RDU.UK GRFS.USA

Address Avinguda de la Generalitat, 152-158, Parque empresarial Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 78% of sales in 2019. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 14% of revenue following the Novartis and Hologic deals.

Product

Business

Information

About

Affiliate Program

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names

Earn affiliate commissions by embedding GuruFocus Charts

GuruFocus Affiliate Program: Earn up to $400 per referral. Detailed

Disclaimers

GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.